Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study

被引:42
作者
Duijkers, IJM
Klipping, C
Verhoeven, CHJ
Dieben, TOM
机构
[1] NV Organon, NL-5340 BH Oss, Netherlands
[2] Dinox Med Invest, NL-6524 TX Nijmegen, Netherlands
关键词
NuvaRing; oral contraceptive; ovarian function; ovulation inhibition; vaginal ring;
D O I
10.1093/humrep/deh493
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: The effects on ovarian function of the combined contraceptive vaginal ring NuvaRing and a combined oral contraceptive (COC) were compared. methods: This randomized, open-label study was performed in 40 healthy female volunteers, who were randomized by a computer-generated list after stratification for the ovulation day in a pretreatment cycle. They received two cycles of NuvaRing (21 subjects) or a COC (30 mug ethinylestradiol and 150 mug levonorgestrel, 19 subjects). NuvaRing was started on cycle day 5, COC on cycle day 1. Follicular diameter, endometrial thickness and FSH, LH, 17beta-estradiol (E-2) and progesterone concentrations were determined. Results: The median maximum follicular diameter (maxFD) was less than or equal to11 mm during treatment. In the first treatment cycle the maxFD was lower in the COC than in the NuvaRing group, due to the different starting procedures. MaxFD were not different in the second treatment cycle. In both groups, E-2 and progesterone levels remained low during treatment. Ovulations did not occur. Conclusions: In both groups, ovarian activity was adequately suppressed. Due to the different starting procedures, lower ovarian activity was observed in the COC group in the first treatment cycle. In the second cycle, ovarian suppression was comparable with NuvaRing and COC treatment.
引用
收藏
页码:2668 / 2673
页数:6
相关论文
共 7 条
[1]   Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring [J].
Dieben, TOM ;
Roumen, FJME ;
Apter, D .
OBSTETRICS AND GYNECOLOGY, 2002, 100 (03) :585-593
[2]   Ovarian function with a novel combined contraceptive vaginal ring [J].
Mulders, TMT ;
Dieben, TOM ;
Bennink, HJTC .
HUMAN REPRODUCTION, 2002, 17 (10) :2594-2599
[3]   Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition [J].
Mulders, TMT ;
Dieben, TOM .
FERTILITY AND STERILITY, 2001, 75 (05) :865-870
[4]   The combined contraceptive vaginal ring, NuvaRing®:: an international study of user acceptability [J].
Novák, A ;
de la Loge, C ;
Abetz, L ;
van der Meulen, EA .
CONTRACEPTION, 2003, 67 (03) :187-194
[5]   PITUITARY AND OVARIAN RESPONSIVENESS TO A GRADED GONADOTROPIN-RELEASING FACTOR STIMULATION TEST IN WOMEN USING A LOW-ESTROGEN OR A REGULAR TYPE OF ORAL-CONTRACEPTIVE [J].
SPELLACY, WN ;
KALRA, PS ;
BUHI, WC ;
BIRK, SA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1980, 137 (01) :109-115
[6]  
TIMMER CJ, 2000, CONTRACEPTION, V59, P311
[7]   Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives [J].
van Heusden, AM ;
Fauser, BCJM .
CONTRACEPTION, 1999, 59 (04) :237-243